ASX:VLSPharmaceuticals
Vita Life Sciences (ASX:VLS) Margin Stability At 11.2% Reinforces Earnings Quality Narrative
Vita Life Sciences FY 2025 Earnings Snapshot
Vita Life Sciences (ASX:VLS) has reported its FY 2025 first half with revenue of A$45.5 million and basic EPS of A$0.086, setting the tone for a year that also saw trailing twelve month revenue reach A$93.3 million and EPS of A$0.186. Over the last few reporting periods the company has seen revenue move from A$39.5 million in 1H FY 2024 to A$40.1 million in 2H FY 2024 and then to A$45.5 million in 1H FY 2025. Over the same periods, basic EPS...